Trial ID or NCT#

NCT02424955

Status

RECRUITING

Purpose

Primary Objective: The primary objectives of this prospective pilot study is to: 1. determine the feasibility and reproducibility of 3D contrast enhanced ultrasound imaging in liver cancer patients undergoing Stereotactic Ablative Radiotherapy and 2. evaluate whether there are treatment induced early changes in imaging metrics derived from 3D contrast enhanced ultrasound. This study will provide valuable insight as to the potential of baseline and/or early post-treatment 3D ultrasound perfusion characteristics (measurements of blood-flow) of primary and metastatic liver tumors to predict tumor response to Stereotactic Ablative Radiotherapy. The investigators' underlying goal is to assess whether early perfusion changes at 1-7 days after SABR initiation can be used as a non-invasive early biomarker for treatment response assessment. Secondary Objectives: Evaluate the feasibility of contrast-enhanced ultrasound-to-CT fusion by assisting three-dimensional (3D) perfusion ultrasound (US) imaging with optical and electromagnetic tracking of the ultrasound probe on patients with liver cancer that will undergo CT for treatment planning and/or response evaluation.

Official Title

Feasibility of 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Albert Koong, MD, PhD
Aya Kamaya, MD
Radiologist
Associate Professor of Radiology (Body Imaging) at the Stanford University Medical Center
Daniel Chang
Radiation oncologist
Sue and Bob McCollum Professor
Juergen K. Willmann, M.D.
Radiologist, Diagnostic radiologist
Professor of Radiology (Body Imaging)
Dimitre Hristov

Contact us to find out if this trial is right for you.

CONTACT

Pooja Pradhan
(650) 725-4099